The other face of depression, reduced positive affect: the role of catecholamines in causation and cure

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Psychopharmacology

• Publication date

  2007-07-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1177/0269881106069938PMID 17050654
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of bupropion SR on specific symptom clusters of depression: analysis of the 31-item Hamilton Rating Scale for depression.

  2025cited by this paper
• Duloxetine in the treatment of major depressive disorder

  2007cited by this paper
• Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

  2006cited by this paper
• Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.

  2006cited by this paper
• Symptoms of fatigue and sleepiness in major depressive disorder.

  2006cited by this paper
• Dopaminergic-based pharmacotherapies for depression.

  2006cited by this paper
• The many faces of fatigue in major depressive disorder.

  2005cited by this paper
• 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL.

  2005cited by this paper
• Ropinirole in Treatment-Resistant Depression: A 16-Week Pilot Study

  2005cited by this paper
• A double-blind comparison of moclobemide and amineptine in the treatment of depressed out-patients

  2005influential reference
• A direct comparison of presenting characteristics of depressed outpatients from primary vs. specialty care settings: preliminary findings from the STAR*D clinical trial.

  2005cited by this paper
• Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials.

  2005cited by this paper
• Empirical Testing of Two Models for Staging Antidepressant Treatment Resistance

  2005cited by this paper
• Dopamine transporter availability in medication free and in bupropion treated depression: a 99mTc-TRODAT-1 SPECT study.

  2005influential reference
• Symptoms of late-life depression: frequency and change during treatment.

  2005cited by this paper
• The neural circuitry of reward and its relevance to psychiatric disorders

  2004cited by this paper
• Disability and quality of life impact of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project

  2004cited by this paper
• Residual symptoms at remission from depression: impact on long-term outcome.

  2004cited by this paper
• Bupropion Sustained Release Treatment Reduces Fatigue in Cancer Patients

  2004cited by this paper
• Assessing the effects of bupropion SR on mood dimensions of depression.

  2004cited by this paper
• A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor.

  2004cited by this paper
• Bupropion in the management of apathy

  2004cited by this paper
• Comparative efficacy and safety of bupropion and placebo in the treatment of depression

  2004cited by this paper
• Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project

  2004cited by this paper
• Preemptive analgesia: is pain less costly when you pre-pay for it?

  2004cited by this paper
• How antidepressants help depression: mechanisms of action and clinical response.

  2004cited by this paper
• Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.

  2004cited by this paper
• Effectiveness of antidepressants: comparative remission rates.

  2003cited by this paper
• Novel aspects of the chemical anatomy of the striatum and its efferents projections.

  2003cited by this paper
• New approaches to managing difficult-to-treat depressions.

  2003cited by this paper
• In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography.

  2003cited by this paper
• Changes in regional cerebral blood flow with venlafaxine in the treatment of major depression.

  2003cited by this paper
• Nucleus Accumbens Dopamine and the Regulation of Effort in Food-Seeking Behavior: Implications for Studies of Natural Motivation, Psychiatry, and Drug Abuse

  2003cited by this paper
• Treating depression to remission.

  2003cited by this paper
• Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder.

  2003cited by this paper
• Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms

  2002cited by this paper
• How do you define remission?

  2002cited by this paper
• Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis.

  2002cited by this paper
• Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism.

  2002cited by this paper
• Achieving gains beyond response

  2002cited by this paper
• Remission in major depressive disorder: a comparison of pharmacotherapy, psychotherapy, and control conditions.

  2002cited by this paper
• Unmasking disease-specific cerebral blood flow abnormalities: mood challenge in patients with remitted unipolar depression.

  2002cited by this paper
• Duloxetine for the treatment of major depressive disorder.

  2002cited by this paper
• Bupropion occupancy of the dopamine transporter is low during clinical treatment

  2002cited by this paper
• Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses?

  2002cited by this paper
• Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders.

  2001cited by this paper
• Role of 5-HT(2C) receptors in the control of central dopamine function.

  2001cited by this paper
• Energy and improved workplace productivity in depression

  2001influential reference
• Can recovery from depression be achieved?

  2001cited by this paper
• Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression.

  2001cited by this paper
• Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo.

  2001cited by this paper
• Psychopathological correlates of reduced dopamine receptor sensitivity in depression, schizophrenia, and opiate and alcohol dependence.

  2001cited by this paper
• Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients?

  2001cited by this paper
• Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

  2001cited by this paper
• Determinants of poor 1‐year outcome of DSM‐III‐R major depression in the general population: results of the Netherlands Mental Health Survey and Incidence Study (NEMESIS)

  2001cited by this paper
• Amotivational Syndrome Associated with Selective Serotonin Reuptake Inhibitors in Children and Adolescents

  2001cited by this paper
• The role of dopamine in the mechanism of action of antidepressant drugs.

  2000cited by this paper
• Cerebral perfusion in chronic fatigue syndrome and depression

  2000cited by this paper
• Sequential improvement of anxiety, depression and anhedonia with sertraline treatment in patients with major depression

  2000cited by this paper
• Bupropion sustained release versus paroxetine for the treatment of depression in the elderly.

  2000cited by this paper
• Serotonin2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat

  2000cited by this paper
• Depressive illness and disability.

  2000influential reference
• Approaches to the enhancement of patient adherence to antidepressant medication treatment.

  2000cited by this paper
• Comparison of pramipexole, fluoxetine, and placebo in patients with major depression

  2000cited by this paper
• PET measurements of brain glucose metabolism and blood flow in major depressive disorder: a critical review

  2000cited by this paper
• A randomized, double-blind placebo-controlled trial of moclobemide in patients with chronic fatigue syndrome.

  2000cited by this paper
• Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders.

  2000cited by this paper
• Neurobiology of the structure of personality: Dopamine, facilitation of incentive motivation, and extraversion

  1999cited by this paper
• The endocrinology of melancholic and atypical depression: relation to neurocircuitry and somatic consequences.

  1999cited by this paper
• Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness.

  1999cited by this paper
• Symptom-based predictors of a 10-year chronic course of treated depression.

  1999cited by this paper
• [Psychopharmacological profile of venlafaxine].

  1999cited by this paper
• DEPRES II (Depression Research in European Society II): a patient survey of the symptoms, disability and current management of depression in the community. DEPRES Steering Committee.

  1999cited by this paper
• Prefrontal Cortical‐Amygdalar Metabolism in Major Depression

  1999cited by this paper
• Onset of disability in depressed and non-depressed primary care patients

  1999cited by this paper
• Residual symptoms in depressed patients who respond acutely to fluoxetine.

  1999cited by this paper
• Depression among high utilizers of medical care

  1999cited by this paper
• A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline.

  1999cited by this paper
• Amisulpride versus Amineptine and Placebo for the Treatment of Dysthymia

  1999cited by this paper
• Profil psychopharmacologique de la venlafaxine

  1999cited by this paper
• Single-Blind, Placebo Phase-in Trial of Two Escalating Doses of Selegiline in the Chronic Fatigue Syndrome

  1998cited by this paper
• Selective serotonin reuptake inhibitors in affective disorders — I. Basic pharmacology

  1998cited by this paper
• Reboxetine versus fluoxetine: an overview of efficacy and tolerability.

  1998cited by this paper
• Dimensional assessment of onset of action of antidepressants: a comparative study of moclobemide vs. clomipramine in depressed patients with blunted affect and psychomotor retardation.

  1998cited by this paper
• A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients.

  1998cited by this paper
• How to improve recognition and diagnosis of depressive syndromes using international diagnostic criteria.

  1998cited by this paper
• Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse.

  1998cited by this paper
• ECT in Texas: 19 months of mandatory reporting.

  1998cited by this paper
• Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate.

  1998cited by this paper
• A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder.

  1998cited by this paper
• Neuroimaging abnormalities in the subgenual prefrontal cortex: implications for the pathophysiology of familial mood disorders

  1998cited by this paper
• Positron emission tomography measurement of cerebral metabolic correlates of tryptophan depletion-induced depressive relapse.

  1997cited by this paper
• The influence of cognitive variables on recovery in depressed inpatients.

  1997cited by this paper
• Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients.

  1997cited by this paper
• Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy.

  1997cited by this paper
• An open study of the efficacy and adverse effects of moclobemide in patients with the chronic fatigue syndrome

  1997cited by this paper
• The efficacy and acceptability of amineptine versus fluoxetine in major depression

  1997influential reference
• Pharmacology of amineptine, an antidepressant agent acting on the dopaminergic system: a review

  1997cited by this paper
• Reboxetine: additional benefits to the depressed patient.

  1997cited by this paper
• A Review of Functional Neuroimaging in Mood Disorders: Positron Emission Tomography and Depression

  1997cited by this paper

• The impact of timing on bright light therapy: Alleviating anhedonia and circadian rhythm disturbances in depression patients: a randomized controlled trial.

  2026cites this paper
• Characteristics and clinical correlates of persistent anhedonia in the remitted patients with bipolar depression.

  2025cites this paper
• Functional Diversity of Serotonin Neurons in the Dorsal and Median Raphe Nuclei in Emotional Responses

  2025cites this paper
• Between Urges and Actions: Unpacking Affective Dynamics in Nonsuicidal Self-Injury.

  2025cites this paper
• Coadministration of scopolamine and mGlu2 receptor negative allosteric modulator VU6001966 as a potential therapeutic approach for depression: Rat frontal cortex neurochemistry and behavior.

  2025cites this paper
• Vulnerability to chronic stress in male rats: Additive effect of low positive affectivity and high hedonic response as measured by sucrose intake.

  2025cites this paper
• Treatment response to bupropion: an investigation of changes in resting-state functional connectivity in patients with major depressive disorder.

  2025cites this paper
• Transdiagnostic network alterations and associated neurotransmitter signatures across major psychiatric disorders in adolescents: Evidence from edge-centric analysis of time-varying functional brain networks.

  2025cites this paper
• Healthcare Professionals’ Perceptions of Anhedonia in Major Depressive Disorder and the Possibilities of Episodic Future Thinking Training: A Qualitative Study in a Tertiary Care Hospital

  2025cites this paper
• From movement to motivation: a proposed framework to understand the antidepressant effect of exercise

  2024cites this paper
• Development of a multivariate prediction model for antidepressant resistant depression using reward-related predictors

  2024cites this paper
• A rare presentation of stress cardiomyopathy in a patient with ulcerative colitis

  2024cites this paper
• The anti-anhedonic effects of ketamine in the treatment of resistant unipolar and bipolar depression: A systematic review and meta-analysis of current data

  2024cites this paper
• Aesthetic chills modulate reward learning in Anhedonic depression.

  2024cites this paper
• The effects of psychotherapy for anhedonia on subcortical brain volumes measured with ultra-high field MRI.

  2024cites this paper
• Effectiveness of Vortioxetine for the Treatment of Emotional Blunting in Patients with Major Depressive Disorder Experiencing Inadequate Response to SSRI/SNRI Monotherapy in Spain: Results from the COMPLETE Study

  2024cites this paper
• Anhedonia and depression severity measures during ketamine administration in treatment-resistant depression

  2024cites this paper
• Association Between Toxoplasma gondii Infection and Serum Neurotransmitter Levels in Major Depressive Disorder Patients: A Case-Control Study in Bangladesh

  2024cites this paper
• Treatment-resistant depression: molecular mechanisms and management

  2024cites this paper
• Effect of Acute Ketamine Treatment on Sympathetic Regulation Indexed by Electrodermal Activity in Adolescent Major Depression

  2024cites this paper
• Stress to Inflammation and Anhedonia: Mechanistic Insights from Preclinical and Clinical Models.

  2023cites this paper
• Effects of a single dose of amisulpride on functional brain changes during reward- and motivation-related processing using task-based fMRI in healthy subjects and patients with major depressive disorder — study protocol for a randomized clinical trial

  2023cites this paper
• The Serotonin 1A (5-HT_1A) Receptor as a Pharmacological Target in Depression

  2023cites this paper
• Disease progression to bipolar disorder among adolescents and young adults with antidepressant-resistant and antidepressant-responsive depression: Does antidepressant class matter?

  2023cites this paper
• Efficacy, Tolerability, and Safety of Toludesvenlafaxine for the Treatment of Major Depressive Disorder—A Narrative Review

  2023cites this paper
• Positive maternal affect during mother–litter interaction is reduced in new mother rats exhibiting a depression-like phenotype

  2023cites this paper
• Moving from serotonin to serotonin-norepinephrine enhancement with increasing venlafaxine dose: clinical implications and strategies for a successful outcome in major depressive disorder

  2023cites this paper
• Reinforcement-based responsiveness, depression, and anhedonia: A multi-method investigation of intergenerational risk.

  2023cites this paper
• Ventral Tegmental Area M5 Muscarinic Receptors Mediate Effort-Choice Responding and Nucleus Accumbens Dopamine in a Sex-Specific Manner 

  2023cites this paper
• "Don't [ruminate], be happy": A cognitive perspective linking depression and anhedonia.

  2023cites this paper
• Effects of an experimentally induced inflammatory stimulus on motivational behavior in remitted depressed patients.

  2023cites this paper
• Effects of the dopamine depleting agent tetrabenazine in tests evaluating different components of depressive-like behavior in mice: sex-dependent response to antidepressant drugs with SERT and DAT blocker profiles

  2023cites this paper
• Ketamine causes poor maternal care in rats with postpartum depression and leads to few behavioral and neurochemical alterations on male offspring.

  2023cites this paper
• 5-HYDROXITRYPTOPHAN DIETARY SUPPLEMENTATION IN POST-TRAUMATIC STRESS SYNDROME

  2022cites this paper
• Efficacy of adjunctive brexpiprazole on symptom clusters of major depressive disorder: A post hoc analysis of four clinical studies.

  2022cites this paper
• Event-Related Potentials in Women on the Pill: Neural Correlates of Positive and Erotic Stimulus Processing in Oral Contraceptive Users

  2022cites this paper
• Median raphe serotonergic neurons projecting to the interpeduncular nucleus control preference and aversion

  2022cites this paper
• Are mGluR2/3 Inhibitors Potential Compounds for Novel Antidepressants?

  2022cites this paper
• The motivation and energy inventory (MEI): Analysis of the clinically relevant response threshold in patients with major depressive disorder and emotional blunting using data from the COMPLETE study.

  2022cites this paper
• A comprehensive model to understand and assess the motivational background of video game use: The Gaming Motivation Inventory (GMI)

  2022cites this paper
• A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review

  2022cites this paper
• Positive affect, well-being and the human conserved transcriptional response to adversity: a descriptive review

  2022cites this paper
• The impacts of anhedonia on brain functional alterations in patients with major depressive disorder: A resting-state functional magnetic resonance imaging study of regional homogeneity.

  2022cites this paper
• Ketamine use in pediatric depression: A systematic review.

  2022cites this paper
• Postpartum depression in rats causes poor maternal care and neurochemical alterations on dams and long-lasting impairment in sociability on the offspring.

  2022cites this paper
• Effects of GPR139 agonism on effort expenditure for food reward in rodent models: Evidence for pro-motivational actions.

  2022cites this paper
• Contributors of Functional Impairment in Major Depressive Disorder: a Biopsychosocial Approach

  2022cites this paper
• Pharmacological Treatments for Anhedonia.

  2022cites this paper
• Ketamine and Other Glutamate Receptor Antagonists As Fast-Actin

  2022cites this paper
• Treatment-Resistant Depression with Anhedonia: Integrating Clinical and Preclinical Approaches to Investigate Distinct Phenotypes.

  2022cites this paper
• Expectancies for Cannabis- Induced Emotional Breakthrough, Mystical Experiences and Changes in Dysfunctional Attitudes: Perceptions of the Potential for Cannabis-Assisted Psychotherapy for Depression

  2022cites this paper
• Individual- and Connectivity-Based Real-Time fMRI Neurofeedback to Modulate Emotion-Related Brain Responses in Patients with Depression: A Pilot Study

  2022cites this paper
• Recent advances in the psychopharmacology of major depressive disorder

  2022cites this paper
• Journal Pre-proof Effects of GPR139 agonism on effort expenditure for food reward in rodent models: Evidence for pro-motivational actions

  2022cites this paper
• Mediating Role of Rumination between Neuroticism and Depression among the Married and Unmarried Nurses of Multan

  2021cites this paper
• Comparative effectiveness of repeated ketamine infusions in treating anhedonia in bipolar and unipolar depression.

  2021cites this paper
• The Effect of Electroconvulsive Therapy on Positive Affect and Hedonism in Patients With Depression

  2021cites this paper
• Affective Disorders

  2021cites this paper
• Evidence of hypoglycemic anhedonia and modulation by bupropion in rats.

  2021cites this paper
• Antianhedonic Effect of Repeated Ketamine Infusions in Patients With Treatment Resistant Depression

  2021cites this paper
• Neural and genetic correlates of cognitive deficits in major depressive disorder

  2021cites this paper
• Discovering the Lost Reward: Critical Locations for Endocannabinoid Modulation of the Cortico–Striatal Loop That Are Implicated in Major Depression

  2021cites this paper
• Impact of Fluoxetine on Behavioral Invigoration of Appetitive and Aversively Motivated Responses: Interaction With Dopamine Depletion

  2021cites this paper
• Mindfulness-Based Stress Reduction Specifically Improves Social Anhedonia Among Adults with Chronic Stress

  2021cites this paper
• Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders.

  2021cites this paper
• Neuroimmunology of depression.

  2021cites this paper
• Validation of the Oxford Depression Questionnaire: Sensitivity to change, minimal clinically important difference, and response threshold for the assessment of emotional blunting.

  2021cites this paper
• Energizing effects of bupropion on effortful behaviors in mice under positive and negative test conditions: modulation of DARPP-32 phosphorylation patterns

  2021cites this paper
• Symptom specificity of ayahuasca's effect on depressive symptoms

  2021influential citation
• Reward-Related Neural Circuitry in Depressed and Anxious Adolescents: A Human Connectome Project.

  2021cites this paper
• Psicotrópicos y Farmacogenética

  2021cites this paper
• Low Doses of Psilocybin and Ketamine Enhance Motivation and Attention in Poor Performing Rats: Evidence for an Antidepressant Property

  2021cites this paper
• Gender Matters: Nonlinear Relationships Between Heart Rate Variability and Depression and Positive Affect

  2021cites this paper
• Beauty That Moves: Dance for Parkinson’s Effects on Affect, Self-Efficacy, Gait Symmetry, and Dual Task Performance

  2021cites this paper
• Validation of the Chinese Dimensional Anhedonia Rating Scale in Depressed Patients in Hong Kong

  2021cites this paper
• Bupropion increases cerebral activation in auditory affective processing: A randomized controlled fMRI study.

  2021cites this paper
• Virtual Reality Therapy for Depression and Mood in Long-Term Care Facilities

  2021cites this paper
• Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment.

  2020cites this paper
• Translational Assessments of Reward Responsiveness in the Marmoset

  2020cites this paper
• Gratitude and lower suicidal ideation among sexual minority individuals: theoretical mechanisms of the protective role of attention to the positive

  2020cites this paper
• Anticipatory Energization Revealed by Pupil and Brain Activity Guides Human Effort-Based Decision Making

  2020cites this paper
• Beauty That Moves: Dance for Parkinson’s Effects on Affect, Self-Efficacy, Gait Symmetry and Dual Task Performance

  2020cites this paper
• Diminished Reward Responsiveness is Associated with Lower Reward Network GluCEST: An Ultra-High Field Glutamate Imaging Study

  2020cites this paper
• The Effects of the Atypical Dopamine Uptake Inhibitor CE-158 on Extracellular Dopamine in the Nucleus Accumbens

  2020cites this paper
• Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder: A CAN-BIND-1 Report.

  2020cites this paper
• Neuron Terminal Monoamines Related to Resilience, Depression-Like, or Non-Depression-Like Behavioral States in Learned Helplessness Paradigm.

  2020cites this paper
• Molecular Imaging of Depressive Disorders

  2020cites this paper
• Comparative effectiveness of esketamine in the treatment of anhedonia in bipolar and unipolar depression.

  2020cites this paper
• Cognition in mood disorders

  2020cites this paper
• Personalized Psychiatry and Depression: The Role of Sociodemographic and Clinical Variables

  2020cites this paper
• Full title: A pupil-linked arousal mechanism for deciding to engage in future physical effort

  2020cites this paper
• Gratitude and suicide risk among college students: Substantiating the protective benefits of being thankful

  2020cites this paper
• Dopamine and Noradrenaline in the Brain; Overlapping or Dissociate Functions?

  2020cites this paper
• Mission Impossible: Curing my Mental Illnesses

  2020cites this paper
• Lorcaserin: a review of its preclinical and clinical pharmacology and therapeutic potential.

  2020cites this paper
• Effects of Stress-Induced Inflammation on Reward Processing in Healthy Young Women.

  2020cites this paper
• The Effects of Repeated Transcranial Magnetic Stimulation (rTMS) on the Speeded Identification of Happy Faces in Depressed Adults

  2020cites this paper
• Ventral tegmental area GABA neurons mediate stress-induced anhedonia

  2020cites this paper
• Anhedonia in Depression: Mechanisms, Assessment, and Therapeutics

  2019cites this paper
• Threat-related disorders as persistent motivational states of defense.

  2019cites this paper